SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Harmony Biosciences Holdings, Inc. (HRMY) trades at a trailing P/E of 10.2, forward P/E of 8.3. Trailing earnings yield is 9.76%, forward earnings yield 12.12%. PEG 1.28. Graham Number is $30.58.
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (10.2); analyst target implies upside (+59.8%); earnings yield beats bond yields (9.76%).
- Forward P/E 8.3 (down from trailing 10.2) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 1.28 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 9.76% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 12.12% as earnings recover.
- Analyst consensus target $46.80 (+59.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 82/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HRMY
Valuation Multiples
P/E (TTM)10.2
Forward P/E8.3
PEG Ratio1.28
Forward PEG0.27
P/B Ratio1.87
P/S Ratio1.88
EV/EBITDA4.4
Per Share Data
EPS (TTM)$2.75
Forward EPS (Est.)$3.55
Book Value / Share$15.10
Revenue / Share$15.07
FCF / Share$6.04
Yields & Fair Value
Earnings Yield9.76%
Forward Earnings Yield12.12%
Dividend Yield0.00%
Graham Number$30.58
SharesGrow IV$82.41 (+181.4%)
Analyst Target$46.80 (+59.8%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
-45.7 |
0.00 |
22.35 |
0.00 |
- |
| 2019 |
-15.5 |
-0.14 |
-203.43 |
393.12 |
- |
| 2020 |
-55.7 |
0.90 |
21.16 |
12.87 |
- |
| 2021 |
70.9 |
-0.46 |
13.15 |
8.03 |
- |
| 2022 |
18.0 |
0.04 |
8.09 |
7.45 |
- |
| 2023 |
14.9 |
-0.51 |
4.11 |
3.30 |
- |
| 2024 |
13.5 |
0.75 |
2.97 |
2.74 |
- |
| 2025 |
13.6 |
1.74 |
2.47 |
2.48 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.81 |
$0.00 |
$-39.9M |
- |
| 2019 |
$-2.48 |
$6M |
$-158.05M |
-2636.4% |
| 2020 |
$-0.91 |
$159.74M |
$-51.86M |
-32.5% |
| 2021 |
$0.58 |
$305.44M |
$34.6M |
11.3% |
| 2022 |
$2.97 |
$437.86M |
$181.47M |
41.4% |
| 2023 |
$2.13 |
$582.02M |
$128.85M |
22.1% |
| 2024 |
$2.51 |
$714.73M |
$145.49M |
20.4% |
| 2025 |
$2.71 |
$868.45M |
$158.69M |
18.3% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$3.55 |
$2.69 – $4.34 |
$1.02B |
$983.93M – $1.05B |
7 |
| 2027 |
$4.22 |
$3.47 – $5.26 |
$1.15B |
$952.34M – $1.28B |
6 |
| 2028 |
$4.87 |
$1.45 – $6.48 |
$1.22B |
$1.22B – $1.22B |
9 |
| 2029 |
$5.17 |
$4.43 – $5.65 |
$1.26B |
$1.12B – $1.35B |
3 |
| 2030 |
$4.53 |
$3.88 – $4.95 |
$1.06B |
$943.97M – $1.14B |
3 |
